A Single-center, Randomized, 2-Period, Crossover, Study to Explore The Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of EOS789 in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis
Latest Information Update: 18 Dec 2023
At a glance
- Drugs EOS 789 (Primary) ; Sevelamer (Primary)
- Indications Hyperphosphataemia; Renal failure
- Focus Adverse reactions
- Sponsors Chugai Pharmaceutical
- 13 Dec 2023 According to Alebund Pharmaceuticals media release, Dr. Moe has been principal investigators of this trial.
- 12 Sep 2018 Status changed from active, no longer recruiting to completed.
- 25 Jul 2018 Planned End Date changed from 1 Dec 2019 to 1 Aug 2018.